Bruno LinetzkyFollowEli Lilly (United States)1 paperORCID 0009-0009-4015-7794OpenAlexPapersAmerican Journal of Preventive CardiologyHuman trial·2 hStudy design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertensionGLP-1 receptor agonists
American Journal of Preventive CardiologyHuman trial·2 hStudy design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertensionGLP-1 receptor agonists